Patents by Inventor Sara Arab
Sara Arab has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210241178Abstract: Embodiments discussed herein facilitate determination of risk of relapse of AML post-transplant. One example embodiment is a method, comprising: accessing a digital whole slide image (WSI) comprising a post-transplant bone marrow aspirate from a patient that has acute myeloid leukemia (AML); segmenting one or more myeloblasts on the digital WSI; extracting one or more features from the segmented one or more myeloblasts; providing the one or more features extracted from the segmented one or more myeloblasts to a trained machine learning model; and receiving, from the trained machine learning model, an indication of a risk of relapse of the AML.Type: ApplicationFiled: February 4, 2021Publication date: August 5, 2021Inventors: Anant Madabhushi, Sara Arab Yarmohammadi, Zelin Zhang, Patrick Leo, Leland Metheny, Howard Meyerson
-
Patent number: 10234462Abstract: The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.Type: GrantFiled: January 26, 2012Date of Patent: March 19, 2019Assignee: Roche Diagnostics Operations, Inc.Inventors: Dirk Block, Sara Arab, Georg Hess, Hendrik Huedig, Peter Liu, Ursula-Henrike Wienhues-Thelen
-
Publication number: 20160146836Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker CRYAB, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure selected from the group consisting of a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation, and of assessing heart failure by comparing the concentration determined in for CRYAB and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of CRYAB as a marker protein in the assessment of heart failure, a marker combination comprising CRYAB and a kit for measuring CRYAB.Type: ApplicationFiled: January 27, 2016Publication date: May 26, 2016Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Dirk Block, Hendrik Huedig, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Sara Arab
-
Publication number: 20140193845Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.Type: ApplicationFiled: February 14, 2014Publication date: July 10, 2014Applicants: The Governing Council of the University of Toronto, Roche Diagnostics Operations, Inc.Inventors: Ursula-Henrike Wienhues-Thelen, Sara Arab, Dirk Block, Andrew Emili, Anthony Gramolini, Georg Hess, Hendrik Huedig, Peter Liu, David MacLennan
-
Patent number: 8691587Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.Type: GrantFiled: October 11, 2010Date of Patent: April 8, 2014Assignee: Roche Diagnostics Operations, Inc.Inventors: Ursula-Henrike Wienhues-Thelen, Sara Arab, Dirk Block, Andrew Emili, Anthony Gramolini, Georg Hess, Hendrik Heudig, Peter Liu, David MacLennan
-
Publication number: 20120156703Abstract: The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.Type: ApplicationFiled: January 26, 2012Publication date: June 21, 2012Applicants: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, ROCHE DIAGNOSTICS OPERATIONS, INC.Inventors: Dirk Block, Sara Arab, Georg Hess, Hendrik Huedig, Peter Liu, Ursula-Henrike Wienhues-Thelen
-
Publication number: 20110165591Abstract: The invention relates to a method for assessing heart failure in vitro and involves the steps of measuring in a sample the concentration of the marker biglycan, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for biglycan and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of biglycan as a marker protein in the assessment of heart failure, a marker combination comprising biglycan and a kit for measuring biglycan.Type: ApplicationFiled: March 15, 2011Publication date: July 7, 2011Inventors: Ursula-Henrike Wienhues-Thelen, Sara Arab, Dirk Block, Andrew Emili, Anthony Gramolini, Georg Hess, Hendrik Huedig, Peter Liu, David MacLennan
-
Publication number: 20110027819Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.Type: ApplicationFiled: October 11, 2010Publication date: February 3, 2011Inventors: Ursula-Henrike Wienhues-Thelen, Sara Arab, Dirk Block, Andrew Emili, Anthony Gramolini, Georg Hess, Hendrik Heudig, Peter Liu, David MacLennan
-
Patent number: 7335750Abstract: Hybrid compounds comprising a first domain and a second domain are provided. The first domain and the second domain are preferably covalently linked, and the first domain comprises a domain which is capable of specific binding to Gb3; and the second domain comprising a moiety selected from the group consisting of drug moiety, a nucleic acid, a probe, a polypeptide, and a hook, with the proviso that the second domain is not a verotoxin or a fragment thereof. Methods of preparing and using the hybrid compounds are also provided.Type: GrantFiled: November 18, 2002Date of Patent: February 26, 2008Assignee: Hospital for Sick Children Research and Development Limited PartnershipInventors: Sara Arab, Clifford A. Lingwood, Aye-Aye Khine
-
Publication number: 20030068323Abstract: Hybrid compounds comprising a first domain and a second domain are provided. The first domain and the second domain are preferably covalently linked, and the first domain comprises a domain which is capable of specific binding to Gb3; and the second domain comprising a moiety selected from the group consisting of drug moiety, a nucleic acid, a probe, a polypeptide, and a hook, with the proviso that the second domain is not a verotoxin or a fragment thereof. Mehtods of preapring and using the hybrid compounds are also provided.Type: ApplicationFiled: November 18, 2002Publication date: April 10, 2003Applicant: Hospital for Sick Children Research and Development Limited PartnershipInventors: Sara Arab, Clifford A. Lingwood, Aye-Aye Khine
-
Patent number: 6482586Abstract: Hybrid compounds comprising a first domain and a second domain are provided. The first domain and the second domain are preferably covalently linked, and the first domain comprises a domain which is capable of specific binding to Gb3; and the second domain comprising a moiety selected from the group consisting of drug moiety, a nucleic acid, a probe, a polypeptide, and a hook, with the proviso that the second domain is not a verotoxin or a fragment thereof. Mehtods of preapring and using the hybrid compounds are also provided.Type: GrantFiled: November 21, 1997Date of Patent: November 19, 2002Assignee: Hospital for Sick Children Research and Development Limited PartnershipInventors: Sara Arab, Clifford A. Lingwood, Aye-Aye Khine
-
Publication number: 20020099002Abstract: The invention pertains to methods for inhibiting angiogenesis. Diagnostic and therapeutic methods utilizing anti-angiogenic agents which bind Gb3 or CD77, e.g., verotoxins, are provided. Methods for treating multiple drug resistant tumors are also provided.Type: ApplicationFiled: June 8, 2001Publication date: July 25, 2002Applicant: Hospital for Sick Children Research and Development Limited Partnership at Reel 010228Inventors: Sara Arab, Clifford A. Lingwood